Mallea-Gil, Maria SusanaBernabeu, IgnacioSpiraquis, AdrianaAvangina, AlejandraLoidi, LourdesBallarino, Carolina2017-10-302017-10-302016Maria Susana Mallea-Gil, Ignacio Bernabeu, Adriana Spiraquis, Alejandra Avangina, Lourdes Loidi, and Carolina Ballarino, “Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A128 Mutation,” Case Reports in Endocrinology, vol. 2016, Article ID 2087102, 5 pages, 2016. doi:10.1155/2016/20871022090-6501http://hdl.handle.net/10347/16081Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented adverse effects is reversible elevation of hepatic enzymes. We report a 39-year-old male acromegalic patient with a pituitary macroadenoma who underwent transsphenoidal surgery. The patient’s condition improved but GH and IGF-I levels did not normalize; as a consequence, we first administered dopamine agonists and then somatostatin receptor ligands (SRLs) with poor response. PEGv 15mg every other day was added to lanreotide 120mg monthly. The patient developed a severe hepatitis five months after starting the combination therapy. Elevated ferritin, iron, and transferrin saturation suggested probable hepatitis due to haemochromatosis. We performed a liver biopsy which showed an acute cholestatic hepatitis consistent with toxic etiology. A heterozygous genotype UGT1A1∗28 polymorphism associated with Gilbert’s syndrome was also found in this Argentine patient. The predominant clinical presentation resembled an acute cholestatic hepatitis associated with severe hemosiderosis, a different and new pattern of PEGv hepatotoxicityeng© 2016 Maria Susana Mallea-Gil et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly citedhttps://creativecommons.org/licenses/by/4.0/journal article10.1155/2016/20871022090-651Xopen access